Albert Augustus (Gus) Davis is a neurologist and neuroscientist with interests in protein aggregation, neuroinflammation and mechanisms underlying neuron injury and death in neurodegenerative diseases. His research focuses on understanding the molecular events that influence pathological aggregation and clearance of disease-associated proteins in Lewy body disease, a group of disorders that includes Parkinson’s disease (PD) and dementia with Lewy bodies. His laboratory has developed expertise in cell and preclinical models to investigate protein aggregation and neurodegeneration. He has assisted with multiple clinical studies and trials, and he served as the biofluid core co-leader for the North American Prodromal Synucleinopathy, Stage 2 (NAPS2) U19 protocol. Dr. Davis will integrate alpha-synuclein seed amplification assays with additional clinical, biofluid and neuroimaging data as part of a comprehensive analysis in participants with REM sleep behavior disorder to pave the way for disease-modifying therapies for PD and related neurodegenerative diseases.